On April 13, 2023 IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, reported the presentation of six posters at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023, taking place in Orlando, Florida on April 14-19, 2023 (Press release, IGM Biosciences, APR 13, 2023, View Source [SID1234630050]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are proud to show the breadth and depth of our oncology pipeline at this year’s AACR (Free AACR Whitepaper) meeting, as the emerging data from our clinical and pre-clinical efforts on IGM-8444, IGM-7354, IGM-2644, IGM-2537 and imvotamab continue to demonstrate the potential for encouraging anticancer activity coupled with favorable safety profiles," said Chris Takimoto, M.D., Ph.D., F.A.C.P., Chief Medical Officer of IGM Biosciences. "Looking ahead, we look forward to continued dosing in our randomized clinical trial of IGM-8444 in combination with standard of care FOLFIRI chemotherapy and bevacizumab in second line metastatic colorectal cancer patients and in our initial clinical study of IGM-7354 in patients with solid tumors. We are also excited to be initiating clinical studies of IGM-2644, our CD38 x CD3 T cell engaging IgM antibody, which we hope will prove to be a safe and more potent form of anti-CD38 therapy for multiple myeloma, including for patients who have previously been treated with daratumumab. We look forward to providing continued updates on these exciting oncology programs."

Presentation details are as follows:

Poster Number: 2933
Title: Novel CD123xCD3 bispecific IgM antibody, IGM-2537, potently induces T-cell mediated cytotoxicity of acute myeloid leukemia cells with minimal cytokine release
Presenter: Gene Li, Ph.D., Senior Scientist, Immuno-oncology, IGM Biosciences
Session Date: Monday, April 17
Session Time: 1:30 – 5:00 PM ET

Poster Number: 2959
Title: Novel CD38xCD3 bispecific IgM T cell engager, IGM-2644, potently kills multiple myeloma cells though complement and T cell dependent mechanisms
Presenter: Keyu Li, Ph.D., Associate Director, IGM Biosciences
Session Date: Monday, April 17
Session Time: 1:30 – 5:00 PM ET

Poster Number: 5660
Title: IGM-7354, an immunocytokine with IL-15 fused to an anti-PD-L1 IgM, induces NK and CD8+ T cell mediated cytotoxicity of PD-L1-positive tumor cells
Presenter: Thierry D. Giffon, Ph.D., Senior Scientist, Immuno-oncology, IGM Biosciences
Session Date: Tuesday, April 18
Session Time: 1:30 – 5:00 PM ET

Poster Number: 4120
Title: Depletion of tissue-resident B cells by a CD20xCD3 IgM bispecific T cell engager in cynomolgus monkeys demonstrates effective tissue penetration and potent target cell killing
Presenter: Miho Oyasu, Ph.D., Associate Director, IGM Biosciences
Session Date: Tuesday, April 18
Session Time: 9:00 AM – 12:30 PM ET

Poster Number: 6123
Title: Characterization of the synergistic tumor cytotoxicity of agonistic DR5 IgM antibody IGM-8444 with chemotherapeutic agents
Presenter: Beatrice T. Wang, Ph.D., Associate Director, IGM Biosciences
Session Date: Wednesday, April 19
Session Time: 9:00 AM – 12:30 PM ET

Poster Number: CT052
Title: A phase 1/2 randomized study of imvotamab monotherapy and in combination with loncastuximab tesirine in relapsed/refractory non-Hodgkin lymphomas
Presenter: Catherine Diefenbach, M.D., Director of Hematology Translational Research, NYU Langone Perlmutter Cancer Center
Session Date: Monday, April 17
Session Time: 9:00 AM – 12:30 PM ET